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Science & SocietyEvery year, hundreds of promising basic discoveries in
the pharmacological field are lost and will never have a
chance to be exploited for patients due to difficulties in
clinical translation. This is especially true for most neuro-
degenerative disorders lacking disease-modifying ther-
apies. Here we present the current scenario and our
vision of a ‘collective-impact’ multistakeholder approach
to expedite the development of new drugs.
Call to action: patients need new therapies
Despite progress in innovative therapies for several hu-
man diseases, approaches to mental and neurological dis-
orders remain comparatively disappointing. In Europe, the
burden of brain disorders was s798 billion in 2010 [1]. Oth-
er Western countries such as the USA, Canada, and Japan
face similar challenges. In this scenario, the market for
drugs is enormous. However, for the degenerative forms of
these disorders, such as Alzheimer’s and Parkinson’s dis-
eases, and progressive multiple sclerosis (MS), no disease-
modifying drugs are yet available. One reason is that, in
this area, R&D tools are mostly unproven. These include:
(i) predictive experimental disease models; (ii) markers to
assess the activity of drug candidates on targets; (iii)
surrogate measures and biomarkers to detect disease ini-
tiation and progression; and (iv) sensitive and robust
clinical measurements. Drug developers must make large
bets on putative drug targets and perform clinical trials
before knowing whether their faith has been well placed.
Because of this (and because of the intrinsic chronic fea-
tures of these diseases), clinical trials have been extraor-
dinarily expensive and often unsuccessful. In the past 10–
15 years, pharmaceutical companies (Pharma) have con-
centrated efforts and investments mainly on less risky
‘low-hanging fruits’, contributing to the so-called ‘innova-
tion crisis’ [2,3]. To meet the challenge, it is mandatory to
revitalize innovation and become far more effective in
building relationships along the entire drug-discovery
and -development pathway with all involved stakeholders
including, academia, government and regulatory agencies,
patient and health foundations, biotechnological compa-
nies (Biotechs), and Pharma [2].
New companies and academia as sources of innovation
Starting in the 1990s, Biotechs based on innovative ideas
mostly coming from academia started developing drugs for
still-unmet medical needs. Of 252 new drugs approved by0165-6147/
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Biotechs or academia [4]. Now, due to diminished early-
stage venture capital for Biotechs and reduced public
funding to academia, these two actors do not often have
the required resources to sustain innovation. Moreover,
due to growing early-stage research costs, Pharma and
venture capitalists have started focusing on the late, Phase
II/III stages of clinical research [3]. As a consequence, a
translational gap, often referred to as the ‘Valley of Death’
[5], appears between Pharma on the one hand, waiting for
de-risked programs, and Biotechs/academia on the other
hand, doing all they can to move their programs across the
Valley.
How to fill the translational gap: the role of foundations
To foster the discovery of new therapies, nonprofit health
organizations and patient foundations have taken a grow-
ing role in intervening at distinct levels in the R&D pro-
cess. For example, health and patient foundations have
often represented a major funding source for disease-spe-
cific basic research [2]. In 2012 alone, patient and health
foundations distributed approximately US$1.5 billion in
the UK and USA ([6], see Table S2). This has represented a
meritorious mechanism to keep innovation alive, as
reflected by increasing numbers of high-impact-factor
breakthrough publications on disease-related basic re-
search. For example, the Italian MS Society (AISM),
through its foundation (FISM, http://www.aism.it/index.-
aspx?codpage=intro_aism_fism_eng) has long been invest-
ing in research (s47.4 million in the past 24 years). In
2013, s6.3 million devoted to research of excellence in MS
has generated 140 scientific publications with a mean
impact factor of 5.9. Sometimes, to accelerate innovation,
foundations have adopted a successful ‘orphan-disease’
approach. In orphan diseases, once a research program
has identified a new potential therapeutic target, financial
support mechanisms for further preclinical and clinical
development dissipate quickly. To solve this problem, in
a similar manner to the National Institutes of Health
(NIH) (see, for example, the Therapeutics for Rare and
Neglected Diseases program [7]), some patient organiza-
tions for neurodegenerative diseases have created funding
mechanisms to cover every step from target identification
to the first human clinical trials (see below and, for exam-
ple, [8–10]).
Foundations have also started building on the develop-
ment of appropriate performance metrics for researchers
(invention disclosures, patents, licenses), and applying a
milestone-driven and go/no-go decision approach.
Academia often lacks drug-discovery assets such as ex-
pertise, tools, and equipment. Foundations and nonprofit
entities can provide academics with the right translational
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support preclinical/clinical database generation and data
sharing to be mined for key tools such as biomarkers. For
example, the NIH have created the Molecular Libraries
Program and the National Chemical Genomics Center, with
a screening capacity equivalent to that of major Pharma.
Many patient foundations have become indispensable part-
ners in the clinical research enterprise by developing, refin-
ing, and validating clinical end points for their diseases
[8]. Examples of such foundations and efforts include Fast
Forward, created by the National MS Society (USA), as well
as the work of the Michael J. Fox and Alzheimer’s Drug
Discovery foundations.
Multistakeholder initiatives
We believe that the translational gap can be bridged only
by promoting multidisciplinary and integrated efforts
among all relevant stakeholders. In multistakeholder
initiatives, representatives from different sectors work
around a common theme (i.e., to develop new therapies
for patients’ benefit). However, so far, stakeholders have
mostly acted as independent entities through a traditional
silo-type model, according to which academic discoveries
are transferred to Biotechs or directly to Pharma
(Figure 1B). In this scenario, to help fill the translational
gap, health and patient foundations have started adopting
strategies characterized by increasing involvement inAcade
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Figure 1. The changing role of health and patient foundations in the discovery and dev
and patient foundations, including two dimensions: the degree of portfolio managemen
according to the models described in the European Research Area Board Report 2009
that are indicated for each model in the parentheses below. ‘Fund and forget’: Investiga
(bottom-up and trust-based approach). ‘Select and oversee’: The portfolio is driven by fo
also work with other funding agencies to sustain key research infrastructures and resour
for-profit organizations (bottom-up and control-based approach). ‘Commit and integrat
portfolio and projects in collaboration with other key stakeholders (top-down and co
(KalydecoTM) to be used in combination with lumacaftor (VX-809) for people with cysti
expected by the end of 2014 for review, with possible approval in 2015). Adapted fr
discovery and development, in which innovative discoveries are transferred from a
companies (Biotechs) and then to pharmaceutical companies (Pharma) (or directly to P
described funding strategies. (c) Proposed ‘collective-impact’ model, according to which
representatives from different sectors work to achieve the same goal: to develop new the
condition is that, besides being connected to each other (see ‘commit and integrate’
investment (ROI). A backbone organization (infrastructure) coordinating all partners’ acprojects’ governance, development, and advancement
(project management) and by proactive decision making
about the projects that are funded (portfolio management)
[6] (Figure 1A).
The traditional ‘fund-and-forget’ model is character-
ized solely by financial contributions to academia.
According to this model, the main criterion for project
selection is scientific merit, and foundations adopting
this model take a more distant role in portfolio and
project management (‘investigator-driven’ approach).
The efficiency and effectiveness of the fund-and-forget
model in facilitating the translation of health research
into patient benefit is increasingly being questioned [6];
however, as mentioned above, in our experience this
behavior helps to keep innovation alive in disease-related
research.
With the ‘select-and-oversee’ approach, foundations are
driving the portfolio by selecting research topics while
taking a more distant advisory role in project manage-
ment. This behavior has been adopted to support Biotechs
focused on the preclinical and clinical development of
neuroprotective and myelin-repairing molecules, to make
projects more attractive for Pharma and to support the
clinical development of orphan stem-cell therapies (http://
www.mesems.org/index.php?lang=eng).
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elopment of innovative medicines. (A) Interaction models for health organizations
t and the degree of project management. Foundation behaviors are also classified
 (http://ec.europa.eu/research/erab/pdf/erab-study-high-risk-high-gain-2010_en.pdf)
tor driven in nature and characterized solely by financial contributions to academia
undations (top-down and trust-based approach). ‘Open and integrate’: Foundations
ces to develop and advance projects. Characterized by high-level engagement with
e’: Foundations are actively involved in the development and management of both
ntrol-based approach). This model has led to remarkable results, like ivacaftor
c fibrosis (currently in Phase III clinical trial; a New Drug Application to the FDA is
om [6]. (B,C) Multistakeholder initiatives. (B) Traditional silo-type model of drug
cademia (often lacking the appropriate translational assets) to biotechnological
harma). Foundations can support academia and/or Biotechs by using the various
 stakeholders apply a shared-resources and shared-risks approach. In both models,
rapies for patients’ benefit. However, in the collective-impact model, a sine qua non
), all parties involved in expediting the discovery of new drugs have a return of
tivities is believed to be necessary for the implementation of the latter model [14].
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resources to develop and advance projects and ensure that
the outputs of research are preserved and shared. In our
experience, this model has started securing the right
translational assets and supporting preclinical/clinical da-
tabase generation and new clinical endpoints for diseases
[8].
Finally, with the ‘commit-and-integrate’ model, which is
leading to several highly significant successes (Figure 1A),
foundations are actively involved in both portfolio and
project management, in collaboration with other relevant
key stakeholders (multistakeholder initiatives). In Europe,
a relevant example of a multistakeholder initiative is the
Innovative Medicines Initiative 2 (IMI2), which, as part of
the Horizon 2020 Program, will bring together Pharma,
public laboratories, small/medium-sized enterprises, pa-
tient groups, and regulatory agencies with the goal of
delivering the right treatment to the right patient at the
right time for priority diseases (http://www.imi.europa.eu/
content/imi-2).
Multistakeholder initiatives in MS
MS is a demyelinating disease and the most common cause
of neurological disability in adults. The disease starts with a
relapsing–remitting (RR) course and evolves to a progres-
sive phase characterized by the accumulation of irreversible
damage. While major progress has been made in RRMS [9],
treatment for progressive MS remains comparatively dis-
appointing. Based on this need, a collaboration was con-
vened by volunteer and staff leaders from several MS
societies to expedite the development of disease-modifying
therapies [10]. We believe that this is a unique example of a
multistakeholder initiative. For the first time, the Progres-
sive MS Alliance (http://www.progressivemsalliance.org/) is
connecting the world’s leading academics, clinicians, indus-
try, and MS organizations to tackle priority areas to make
real breakthroughs in progressive MS. In an unprecedented
manner, through associations that represent them world-
wide, patients are asking the MS community to share
knowledge and to leverage global resources toward the
common goal of accelerating the development of new thera-
pies for the 1 million people living worldwide with progres-
sive MS.
FISM is using all of the above-described models in an
integrated manner toward innovative treatments and MS-
centered care. FISM has long been investing in disease-
relevant academic research through active management of
progressive MS portfolio opportunities and projects. G pro-
tein-coupled receptor 17 (GPR17) represents an interesting
example. Academic research had shown that this receptor is
expressed by myelin-forming oligodendrocyte precursors
(OPCs). Levels of GPR17 are increased at sites of brain
injury, indicating its involvement in damage and/or repair
[11,12]. GPR17 genetic, pharmacological, and biotechnolog-
ical inhibition impaired OPC maturation, suggesting a role
in myelin repair. Its druggability is precedence based, since
GPR17 belongs to the G protein-coupled receptors family. In
silico modeling and virtual screening, followed by pharma-
cological in vitro confirmation, identified synthetic ligands
to be tested in MS [13]. FISM is now working with academia
in implementing a multistakeholder model to develop554proprietary GPR17 ligands with the desired patient-
centered focus.
The collective-impact multistakeholder model
So far, most multistakeholder initiatives have lacked
shared measurements of impact and supporting infra-
structures to enable true alignment of efforts and account-
ability of results. To secure future successes,
multistakeholder initiatives will have to be further sus-
tained by fostering a collective-impact approach, in which,
besides being deeply coordinated, each party also has its
return of investment (ROI) aligned with the common goal
of developing effective therapies for patients (Figure 1C).
In this model stakeholders will apply a shared-resources
and shared-risks approach focused on clearly defined out-
comes and a common goal.
In the case of the social ROI (SROI), five key conditions
are needed for collective-impact projects: (i) common agen-
da; (ii) shared measurements to track performance; (iii)
mutually reinforcing activities; (iv) continuous, open com-
munication among nonprofits, corporations, and govern-
mental agencies; and (v) a backbone organization (i.e., an
infrastructure with specific skills in project and data man-
agement, in facilitation and communication) supporting
the entire initiative and coordinating actions [14,15].
Certainly this model is ambitious and challenging, since
it requires a transparent and collective approach. It also
has several potential limitations, one of which is the diffi-
culty of quantifying SROI, which is meant to measure
extrafinancial value relative to invested resources. How-
ever, some benefits (as well as some outcomes) cannot
always be monetized. Conversely, one of the dangers of
SROI is that parties may focus on monetization without
following the rest of the process. Moreover, to avoid choos-
ing inappropriate indicators, each party must be clear
about its mission and values and understand how its
activities change the process. Last, but not least, SROI
needs considerable effort and is time and resource inten-
sive [14].
By working with all stakeholders, we envisage that
additional relevant ROIs may still have to be developed
and believe that, to pave the way for breakthrough med-
icines, the collective-impact multistakeholders model
deserves attention and investment.
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